Incidence of Secondary Sclerosing Cholangitis in Hospitalized Long COVID-19 Patients: A Retrospective Single Center Study
Background: SARS-CoV-2 infection and associated COVID-19 disease can lead to critical illness with a risk of developing a multiple organ failure. Subsequently, this may lead to various pathological sequelae, such as secondary sclerosing cholangitis after surviving COVID-19 (SSC-COVID). Objective: Th...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2024-03-01
|
Series: | Diagnostics |
Subjects: | |
Online Access: | https://www.mdpi.com/2075-4418/14/7/745 |
_version_ | 1827286900731281408 |
---|---|
author | Christoph R. Werner Stefano Fusco Katharina Kienzle Stefanie Döbele Kerstin Artzner Nisar P. Malek Dörte Wichmann Siri Göpel |
author_facet | Christoph R. Werner Stefano Fusco Katharina Kienzle Stefanie Döbele Kerstin Artzner Nisar P. Malek Dörte Wichmann Siri Göpel |
author_sort | Christoph R. Werner |
collection | DOAJ |
description | Background: SARS-CoV-2 infection and associated COVID-19 disease can lead to critical illness with a risk of developing a multiple organ failure. Subsequently, this may lead to various pathological sequelae, such as secondary sclerosing cholangitis after surviving COVID-19 (SSC-COVID). Objective: The aim is to retrospectively analyze a cohort of hospitalized patients with first-wave (February 2020–June 2020) SARS-CoV-2 infection and persisting unclear cholangiopathy to determine the incidence of SSC-COVID and its risk factors. Results: A total of 249 patients were hospitalized at the university hospital in Tübingen, Germany, with SARS-CoV-2 infection during the first wave of the pandemic. Of these, 35.3% (88/249) required intensive care treatment; 16.5% (41/249) of them died due to the complications of COVID-19; 30.8% (64/208) of surviving patients could be followed up und were retrospectively analyzed at our center. The incidence of confirmed SSC-COVID was 7.8% (5/64). All SSC-COVID patients had an ICU stay >20 days, for invasive ventilation, positioning treatment, vasopressor treatment, but possible risk factors for SSC were not significant due to the small number of patients. Conclusions: SSC-COVID is an emerging disease in post-COVID patients with a high incidence in our single-center cohort. SSC-COVID should be considered as a differential diagnosis, if unclear cholangiopathy or cholestasis persists after SARS-CoV-2 infection. |
first_indexed | 2024-04-24T10:47:48Z |
format | Article |
id | doaj.art-6f75a580515f4a858b2ec5a6e531b3d2 |
institution | Directory Open Access Journal |
issn | 2075-4418 |
language | English |
last_indexed | 2024-04-24T10:47:48Z |
publishDate | 2024-03-01 |
publisher | MDPI AG |
record_format | Article |
series | Diagnostics |
spelling | doaj.art-6f75a580515f4a858b2ec5a6e531b3d22024-04-12T13:16:51ZengMDPI AGDiagnostics2075-44182024-03-0114774510.3390/diagnostics14070745Incidence of Secondary Sclerosing Cholangitis in Hospitalized Long COVID-19 Patients: A Retrospective Single Center StudyChristoph R. Werner0Stefano Fusco1Katharina Kienzle2Stefanie Döbele3Kerstin Artzner4Nisar P. Malek5Dörte Wichmann6Siri Göpel7Department of Gastroenterology, Gastrointestinal Oncology, Hepatology, Infectious Diseases and Geriatrics, University Hospital Tübingen, Otfried-Müller-Strasse 10, 72076 Tübingen, GermanyDepartment of Gastroenterology, Gastrointestinal Oncology, Hepatology, Infectious Diseases and Geriatrics, University Hospital Tübingen, Otfried-Müller-Strasse 10, 72076 Tübingen, GermanyDepartment of Gastroenterology, Gastrointestinal Oncology, Hepatology, Infectious Diseases and Geriatrics, University Hospital Tübingen, Otfried-Müller-Strasse 10, 72076 Tübingen, GermanyInstitute for Medical Microbiology and Hygiene, University Hospital Tübingen, 72076 Tübingen, GermanyDepartment of Gastroenterology, Gastrointestinal Oncology, Hepatology, Infectious Diseases and Geriatrics, University Hospital Tübingen, Otfried-Müller-Strasse 10, 72076 Tübingen, GermanyDepartment of Gastroenterology, Gastrointestinal Oncology, Hepatology, Infectious Diseases and Geriatrics, University Hospital Tübingen, Otfried-Müller-Strasse 10, 72076 Tübingen, GermanyDepartment of Gastroenterology, Gastrointestinal Oncology, Hepatology, Infectious Diseases and Geriatrics, University Hospital Tübingen, Otfried-Müller-Strasse 10, 72076 Tübingen, GermanyDepartment of Gastroenterology, Gastrointestinal Oncology, Hepatology, Infectious Diseases and Geriatrics, University Hospital Tübingen, Otfried-Müller-Strasse 10, 72076 Tübingen, GermanyBackground: SARS-CoV-2 infection and associated COVID-19 disease can lead to critical illness with a risk of developing a multiple organ failure. Subsequently, this may lead to various pathological sequelae, such as secondary sclerosing cholangitis after surviving COVID-19 (SSC-COVID). Objective: The aim is to retrospectively analyze a cohort of hospitalized patients with first-wave (February 2020–June 2020) SARS-CoV-2 infection and persisting unclear cholangiopathy to determine the incidence of SSC-COVID and its risk factors. Results: A total of 249 patients were hospitalized at the university hospital in Tübingen, Germany, with SARS-CoV-2 infection during the first wave of the pandemic. Of these, 35.3% (88/249) required intensive care treatment; 16.5% (41/249) of them died due to the complications of COVID-19; 30.8% (64/208) of surviving patients could be followed up und were retrospectively analyzed at our center. The incidence of confirmed SSC-COVID was 7.8% (5/64). All SSC-COVID patients had an ICU stay >20 days, for invasive ventilation, positioning treatment, vasopressor treatment, but possible risk factors for SSC were not significant due to the small number of patients. Conclusions: SSC-COVID is an emerging disease in post-COVID patients with a high incidence in our single-center cohort. SSC-COVID should be considered as a differential diagnosis, if unclear cholangiopathy or cholestasis persists after SARS-CoV-2 infection.https://www.mdpi.com/2075-4418/14/7/745secondary sclerosing cholangitisSSCSARS-CoV-2COVID-19long COVID syndromeincidence |
spellingShingle | Christoph R. Werner Stefano Fusco Katharina Kienzle Stefanie Döbele Kerstin Artzner Nisar P. Malek Dörte Wichmann Siri Göpel Incidence of Secondary Sclerosing Cholangitis in Hospitalized Long COVID-19 Patients: A Retrospective Single Center Study Diagnostics secondary sclerosing cholangitis SSC SARS-CoV-2 COVID-19 long COVID syndrome incidence |
title | Incidence of Secondary Sclerosing Cholangitis in Hospitalized Long COVID-19 Patients: A Retrospective Single Center Study |
title_full | Incidence of Secondary Sclerosing Cholangitis in Hospitalized Long COVID-19 Patients: A Retrospective Single Center Study |
title_fullStr | Incidence of Secondary Sclerosing Cholangitis in Hospitalized Long COVID-19 Patients: A Retrospective Single Center Study |
title_full_unstemmed | Incidence of Secondary Sclerosing Cholangitis in Hospitalized Long COVID-19 Patients: A Retrospective Single Center Study |
title_short | Incidence of Secondary Sclerosing Cholangitis in Hospitalized Long COVID-19 Patients: A Retrospective Single Center Study |
title_sort | incidence of secondary sclerosing cholangitis in hospitalized long covid 19 patients a retrospective single center study |
topic | secondary sclerosing cholangitis SSC SARS-CoV-2 COVID-19 long COVID syndrome incidence |
url | https://www.mdpi.com/2075-4418/14/7/745 |
work_keys_str_mv | AT christophrwerner incidenceofsecondarysclerosingcholangitisinhospitalizedlongcovid19patientsaretrospectivesinglecenterstudy AT stefanofusco incidenceofsecondarysclerosingcholangitisinhospitalizedlongcovid19patientsaretrospectivesinglecenterstudy AT katharinakienzle incidenceofsecondarysclerosingcholangitisinhospitalizedlongcovid19patientsaretrospectivesinglecenterstudy AT stefaniedobele incidenceofsecondarysclerosingcholangitisinhospitalizedlongcovid19patientsaretrospectivesinglecenterstudy AT kerstinartzner incidenceofsecondarysclerosingcholangitisinhospitalizedlongcovid19patientsaretrospectivesinglecenterstudy AT nisarpmalek incidenceofsecondarysclerosingcholangitisinhospitalizedlongcovid19patientsaretrospectivesinglecenterstudy AT dortewichmann incidenceofsecondarysclerosingcholangitisinhospitalizedlongcovid19patientsaretrospectivesinglecenterstudy AT sirigopel incidenceofsecondarysclerosingcholangitisinhospitalizedlongcovid19patientsaretrospectivesinglecenterstudy |